Drug Profile
Lotilibcin
Alternative Names: JA 002; JA 002 - topical; WAP-8294A2Latest Information Update: 07 Feb 2018
Price :
$50
*
At a glance
- Originator aRigen
- Class Antibacterials; Depsipeptides; Peptide antibiotics
- Mechanism of Action Cell membrane modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bacterial infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Methicillin-resistant-Staphylococcus-aureus-infections in USA (Topical)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in Japan (IV-infusion)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Skin-and-soft-tissue-infections in USA (Topical, Gel)